Literature DB >> 23620800

A protein prioritization approach tailored for the FA/BRCA pathway.

Anneke Haitjema1, Bernd W Brandt, Najim Ameziane, Patrick May, Jaap Heringa, Johan P de Winter, Hans Joenje, Josephine C Dorsman.   

Abstract

Fanconi anemia (FA) is a heterogeneous recessive disorder associated with a markedly elevated risk to develop cancer. To date sixteen FA genes have been identified, three of which predispose heterozygous mutation carriers to breast cancer. The FA proteins work together in a genome maintenance pathway, the so-called FA/BRCA pathway which is important during the S phase of the cell cycle. Since not all FA patients can be linked to (one of) the sixteen known complementation groups, new FA genes remain to be identified. In addition the complex FA network remains to be further unravelled. One of the FA genes, FANCI, has been identified via a combination of bioinformatic techniques exploiting FA protein properties and genetic linkage. The aim of this study was to develop a prioritization approach for proteins of the entire human proteome that potentially interact with the FA/BRCA pathway or are novel candidate FA genes. To this end, we combined the original bioinformatics approach based on the properties of the first thirteen FA proteins identified with publicly available tools for protein-protein interactions, literature mining (Nermal) and a protein function prediction tool (FuncNet). Importantly, the three newest FA proteins FANCO/RAD51C, FANCP/SLX4, and XRCC2 displayed scores in the range of the already known FA proteins. Likewise, a prime candidate FA gene based on next generation sequencing and having a very low score was subsequently disproven by functional studies for the FA phenotype. Furthermore, the approach strongly enriches for GO terms such as DNA repair, response to DNA damage stimulus, and cell cycle-regulated genes. Additionally, overlaying the top 150 with a haploinsufficiency probability score, renders the approach more tailored for identifying breast cancer related genes. This approach may be useful for prioritization of putative novel FA or breast cancer genes from next generation sequencing efforts.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23620800      PMCID: PMC3631253          DOI: 10.1371/journal.pone.0062017

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


Introduction

Fanconi anemia (FA) is a rare recessive genetically heterogeneous chromosomal instability disorder with both autosomal and X-linked inheritance. FA is associated with haematological defects, including bone marrow failure, aplastic anemia, myelodysplastic syndrome (MDS) and childhood acute myeloid leukemia (AML). Besides these problems, patients have a high risk for solid tumours, such as head and neck squamous cell carcinoma, gynaecological squamous cell carcinoma and esophageal carcinoma. In addition, the patients can present with liver tumours, skin tumours, brain tumours, and renal tumours [1]–[4]. The high cancer risk is generally attributed to impaired repair of DNA damage. Cells from FA patients display chromosomal structural abnormalities. Accordingly, patient-derived cells have turned out to be extremely sensitive to bifunctional alkylating or DNA interstrand cross-linking agents, such as mitomycin C or cisplatin [5], [6]. The latter feature is currently used in standard FA diagnostics. Until now, fifteen complementation groups, FA-A, -B, -C, -D1, -D2, -E, -F, -G, -I, -J, -L, -M, -N, -O, and -P have been described, each corresponding to one distinct gene causing FA [7]–[28]. Recently, the sixteenth novel FA group was found to have mutations in XRCC2 [29]. The FA proteins function together in the FA/BRCA pathway, in which the monoubiquitination of FANCD2 and FANCI is the central event. This ubiquitination reaction is catalyzed by the so-called FA core complex, which consists of eight FA proteins (FANC-A, -B, -C, -E, -F, -G, -L, and -M). The activation of FANCD2 and FANCI recruits the other factors of the pathway, FANCD1/BRCA2, FANCJ/BRIP1, FANCN/PALB2, FANCO/RAD51C, FANCP/SLX4, and XRCC2 to repair DNA damage (Figure 1). Beside these sixteen FA proteins, there are several other proteins associating with the FA core complex, but no mutations in the corresponding genes have thus far been found. These proteins are the Fanconi Anemia Associated Proteins (FAAPs): FAAP100, FAAP24, FAAP20, FAAP16/MHF1, and FAAP10/MHF2 [30]–[33]. A FANCD2/FANCI associated nuclease, FAN1, was also recently identified [34]–[37], as well as a deubiquitinating enzyme complex consisting of USP1 and UAF1 [38], [39]. Intriguingly, most FA proteins were orphan proteins at the time of their discovery, showing no homology to other proteins and harbouring few known protein domains, while displaying a moderate evolutionary conservation. Since not all FA patients could be linked to (one of) the sixteen known complementation groups, new FA genes remain to be identified. In addition, the complex FA network remains to be further unravelled. In a previous study, bioinformatics, based on the properties of known FA proteins, was successfully combined with genetic linkage in identifying a novel FA gene, FANCI from a candidate list [18].
Figure 1

The Fanconi anemia pathway.

For further explanation see main text (newest FA member XRCC2 not shown).

The Fanconi anemia pathway.

For further explanation see main text (newest FA member XRCC2 not shown). The aim of this study is to develop an approach for the identification of proteins of the entire human proteome that potentially interact with the FA/BRCA pathway or are candidate novel FA genes. To this end, we combined a bioinformatic approach based on properties of the first thirteen identified FA proteins with publicly available tools allowing protein ranking.

Materials and Methods

The FA proteins play a pivotal role in genome maintenance, especially during the S phase of the cell cycle (Figure 1). The proteins of the so-called FA core complex monoubiquitinate FANCD2/FANCI resulting in activation of the downstream operating FA proteins. To generate a prioritization of candidate FA/FA-interacting proteins, an integrated approach was developed that involved screening of the entire human proteome (EnsEMBL) using multiple publicly available bioinformatic tools and databases. One of the sixteen known FA genes, FANCI, was discovered via selection of genes based on (general) FA protein properties from a limited number of ∼300 candidate genes [18]. This bioinformatics strategy was incorporated in the selection scheme, using the information of the first thirteen identified FA proteins available at the time. This information was combined with data from publicly available bioinformatic tools and databases. The entire proteome was scanned for peptides with intrinsic properties that are shared by the first thirteen identified FA proteins (FANC-A, -B, -C, -D1, -D2, -E, -F, -G, -I, -J, -L, -M, and -N). The pipeline analysis started with the calculation of nuclear localization scores (WoLF PSORT; [40]) and iso-electric points (EMBOSS IEP; [41]). Orthology/paralogy relationships to mouse were obtained via EnsemblCompara [42], and Gene Ontology (GO [43]; from EnsEMBL), protein interaction data (EnVision 2), biosemantics (Nermal; [44]) and protein function analysis (FuncNet; including the literature mining tool iHop; [45]) were used. The combined information was used for ranking.

Data sources and Tools

All 77454 peptides of the human protein-coding genes were downloaded from EnsEMBL (version 56) using Biomart, together with their corresponding EnsEMBL protein, transcript, and gene IDs (ENSP, ENST, and ENSG). The peptides were used to score the 22413 associated genes. For all protein-coding genes, the associated gene name and database, gene description, Online Mendelian Inheritance in Man (OMIM) morbid and gene accession, and GO cellular component terms were downloaded. The human data were linked to data on mouse. Human to mouse and mouse to human amino acid percentage identity, orthology type and representative (human) protein IDs were retrieved from ComparaGene. The corresponding FASTA sequences of the human proteins were used to calculate the peptide length, iso-electric point (pI; [41]), and Nuclear Localization Signal (NLS; [40]). The GO cellular component annotations for the proteins were analyzed for hierarchic relationships to nucleus (GO:0005634) with the SOAP interface to the Ontology Lookup Service of the European Bioinformatics Institute [46], [47]. Thirteen FA proteins have been used to find interacting proteins using the Molecular Interactions workflow of EnVision 2, Nermal (biosemantics), and FuncNet. The UniProt IDs of the FA proteins have been used as input to the EnVision 2 Molecular Interaction workflow to retrieve interaction data. All thirteen FA proteins were queried against: ChEMBL, DIP, IntAct, iRefIndex, MatrixDB, MINT, MPIDB, Reactome, and Reactome-Functional-Interactions (STRING and BioGrid were not available at the time). Databases that returned output were: DIP, IntAct, iRefIndex, MINT, and Reactome. Next, all UniProt/RefSeq IDs were taken and mapped to EnsEMBL peptide IDs with the Protein Identifier Cross-Reference service (PICR; [48]). Nermal is a text-mining tool that predicts protein-protein interaction based on the similarity of the context in which proteins appear in the literature [44]. The entire matrix with the full set of all human protein-pair match scores was downloaded from the Nermal website. Since we used thirteen FA proteins, each query protein can have interactions with more than one FA protein. In case multiple interactions are present with the FA cluster, the maximum score of the query protein with any of these thirteen FA proteins was taken. Proteins interacting with one of the thirteen FA proteins according to Nermal were listed. Further, FuncNet, a web-based protein function prediction tool [45] was used to give prediction scores to the whole proteome. The thirteen FA proteins were used as reference set while the entire human proteome was divided over several query sets. The FuncNet and Nermal scores were integrated and a new Fisher score was calculated that includes all FuncNet P-values as well as a P-value for Nermal.

Results and Discussion

The FA pathway consists of sixteen FA proteins and many associating proteins. However, still unclassified FA patients exist, which have no gene defect in any of the described complementation groups or in the associating genes/proteins. This suggests that there are more genes/proteins involved in this pathway. Since the unclassified patient groups are very small or even consist of a single person, discovery of the gene by linkage analysis is hard. Modern techniques, such as whole genome sequencing of DNA from unclassified FA families, result in many candidate genes. Therefore, to further elaborate which proteins participate in the FA pathway, we used the pathway itself to screen the whole proteome for similar proteins.

Properties of FA Proteins

During the identification of FANCI the protein properties of existing FA proteins were used to narrow down the candidate list generated by genetic linkage [18]. Since we could use protein properties to distinguish more likely candidates we decided for a genome wide approach. We first compared the intrinsic protein properties of thirteen established FA proteins in order to determine several ‘common’ FA ranges. The following protein properties have been compared between the first thirteen identified FA proteins and the latest identified FA proteins, FANCO/RAD51C, FANCP/SLX4, and XRCC2: i) human-mouse conservation (%ID aa); ii) Nuclear Localization Signal (NLS) score; iii) iso-electric points (pI); iv) subcellular localization, and v) mRNA expression patterns in normal tissues (Table 1; first 4 criteria, all sixteen described FA proteins).
Table 1

Overview of the main intrinsic protein properties of sixteen FA proteins.

Percentage identity (aa)
GeneHuman-MouseMouse-HumanNLS scorepILength (aa)Cellular localization
FANCA65660.866.571455N/C
FANCG7272−0.475.13622N/C
FANCB49490.957.65859N
FANCL7879−0.476.42375N/C
FANCC6763−0.476.09558N/C
FANCE65*EnsEMBL:4166*EnsEMBL:530.704.89536N
FANCF47*EnsEMBL:N/A51*EnsEMBL:N/A−0.479.20374N
FANCM63640.766.002048N
FANCD27374−0.036.191471N
FANCI80801.706.721328N
FANCD1/BRCA256581.026.703418N
FANCN/PALB258630.766.411186N
FANCJ/BRIP169741.136.911249N
FANCO/RAD51C7675−0.476.73376N
FANCP/SLX451604.915.951834N
XRCC27778−0.475.95280N

NLS score: Nuclear Localization Signal score. pI: iso-electric point. Cellular localization: N = Nucleus; N/C = Nucleus and Cytoplasm. *These percentages have been calculated using RefSeq sequences as the orthologs assignment in EnsEMBL were incorrect. FANCE: EnsEMBL’s ortholog mouse protein incorrect; FANCE: NP_068741 (human: 100% identical with ENSP00000229769) and NP_001157291 (mouse). FANCF: no mouse ortholog available in EnsEMBL. FANCF: NP_073562.1 (human: 100% identical with ENSP00000330875) and NP_001108559.1 (mouse).

NLS score: Nuclear Localization Signal score. pI: iso-electric point. Cellular localization: N = Nucleus; N/C = Nucleus and Cytoplasm. *These percentages have been calculated using RefSeq sequences as the orthologs assignment in EnsEMBL were incorrect. FANCE: EnsEMBL’s ortholog mouse protein incorrect; FANCE: NP_068741 (human: 100% identical with ENSP00000229769) and NP_001157291 (mouse). FANCF: no mouse ortholog available in EnsEMBL. FANCF: NP_073562.1 (human: 100% identical with ENSP00000330875) and NP_001108559.1 (mouse). As described previously [18], a significant subset of FA genes encoded orphan proteins at the time of their discovery. The mouse orthologs of the FA proteins display between ∼50 to ∼80% amino acid identity with the corresponding human protein. FANCF has the lowest conservation with an amino acid identity of 47% with its mouse ortholog, FANCI the highest with 80%, while the average for 16 FA proteins is 65% (Table 1). With WoLF PSORT, a subcellular localization prediction has been generated based on the amino acid sequences. FA proteins with a positive NLS score are: FANC-A, -B, -E, -M, -I, -D1, -N, -J, and -P, with an average score of 1.42 (a score of NLS >1 means a predicted specificity of 71% of being nuclear). The FA core complex is assembled from subcomplexes [49], and intriguingly always one member of the subcomplex has a positive NLS score. The score of the most recently identified member of the FA protein family, FANCP/SLX4, turned out to be high (4.91) in comparison to other FA proteins. This may suggest that the prime function of FANCP/SLX4 is in the nucleus, while other FA proteins, such as FANCA and FANCG, may have cytoplasmic functions too. The isoelectric point (pI) of proteins gives information about the function of proteins. Almost all FA proteins have an acidic pI, except FANCB (7.65) and FANCF (9.20) with the average isoelectric point constituting 6.5. Interestingly, the pI of interacting proteins is usually different, but together result in an optimum pH for the desired location [50], [51]. For example, the isoelectric points of the subcomplex: FANCC-FANCE-FANCF, respectively 6.09, 4.89, 9.20, result in an average pI of 6.73. Proteins that participate in the same pathway usually display similar tissue-specific expression patterns. With GeneNote [52], it is possible to survey mRNA expression levels for a selected number of tissues. In general, the expression pattern of GeneNote profiles for FA genes ranged between normalized intensity values of ∼10–100 and was similar between the different assayed tissues, although the profile for FANCG was at the higher end of intensity. The same holds true for FANCF and FANCP/SLX4, which, also for other features, belonged to the extremes (compared to the other FA proteins, FANCF has the highest pI, and FANCP/SLX4 the highest NLS, see also Table 1). FANCF is also an exception in that it is the only one-exon FA gene. The overall picture emerging from these characterization studies is that the vast majority of FA proteins are not highly conserved, already previous described for FANC-A, -B, -C, -D1, -D2, -E, -F, and -G [53]; NLSs - if present - are of moderate strength, proteins are acidic and the corresponding mRNAs are ubiquitously, but not highly, expressed.

Retrieval of Information and Scoring of the Complete Proteome

The same features as queried for the FA proteins were also interrogated for the complete human proteome. Corresponding orthologous mouse-human identities were retrieved. The NLS and pI scores were calculated using the peptide sequences. In addition, other features were retrieved including whether the genes could be linked to specific annotations, such as to Gene Ontology, but also to MIM gene or MIM morbid. Furthermore, all proteins were queried against the 1) Molecular Interactions workflow of EnVision 2) the literature mining tool Nermal and 3) protein function prediction tool FuncNet. It should be noted that in principle for each protein/peptide, features, such as pI and NLS scores, can be determined, while for other queries especially when using the tools related to protein function only a subset of all proteins queried may return results. The ranking scheme consists of two parts, one using the protein and another using retrieved literature data as starting point. The first part can be further subdivided in calculable features (NLS and pI), and other features, such as connection to Gene Ontology terms (Table 2).
Table 2

Scoring scheme.

FiltersSettingsScoreRemarks
Protein
% ID aa and Mouse % ID>40<85%1.5
Difference % ID≤15%2If %ID is in the interval (40< %ID <85) and the difference between human and mouse %ID is ≤15∶0.5 point extra (2 points in total)
Peptide length≤100 aaOnly peptides longer than 100 aa are scored
pI4<pI <91
NLS≤21The score is linearly decreased from 1 to 0 between an NLS increase from 2 to 5
2< NLS ≤5(1,0]
GO NucleusNucleus1Nucleus means GO accession equal to or descendant of nucleus
Unknown0
Different−1
Molecular Interaction (EnVision 2)Present1
Not present0
Literature
MIM annotationPresent1
Not present0
Nermal and FuncNet* Present1.5×Fisher normalized
Not present−1000

The FuncNet and Nermal scores were integrated and a new Fisher score was calculated that includes all FuncNet P-values as well as a P-value for Nermal. The “−1000” score is merely to clearly separate entries with Nermal/FuncNet scoring from those without. The maximum score possible with this scheme is 8.5.

The FuncNet and Nermal scores were integrated and a new Fisher score was calculated that includes all FuncNet P-values as well as a P-value for Nermal. The “−1000” score is merely to clearly separate entries with Nermal/FuncNet scoring from those without. The maximum score possible with this scheme is 8.5. First, the FA protein properties described above were used to aid the scoring of the whole proteome for FA-like proteins. The settings for ranking were based on properties from the first thirteen identified FA proteins, while the most recently identified FA proteins, FANCO/RAD51C [26] and XRCC2 [29] were used for validation, and FANCP/SLX4 [27], [28] was used for fine-tuning. The percentage of identity between human and mouse protein was set between 40 and 85%. Points were given when a protein has an identity within this range. Extra weight was given if the human and mouse orthologs were more similar (i.e. when the difference in percentage identity of amino acids between human-mouse and vice versa was less than or equal to 15%). For the NLS scores, one point was given to a protein if an NLS score ≤2 was detected, which is in line with the thirteen FA proteins. However, the later identified, FANCP/SLX4, which harbours a high NLS score, would not obtain a score. To cover for this extreme, we developed a scoring in which the presence of NLS scores in the higher ranges from 2 to 5 resulted in a linear decrease in assigned points, ranging from 1 to 0. In total 94% of the peptides analysed displayed scores between −0.47 and 2.00, and therefore received points. The pI range chosen, 4 Second, we expanded the scoring of the proteome with publicly available interaction data. If a protein in the proteome has an interaction with at least one of the thirteen FA proteins according to the EnVision 2 Molecular Interaction results, one point was given. Further, a point was given when an OMIM entry was present; this was primarily to give known genes, including those not yet related to DNA repair pathways, a higher weight. Often, the genes were already known for a long time (e.g. RAD51C) but not yet related to FA. In addition, known genes in ranked lists can be easier ruled out/or selected for often laborious further analysis as more information is present on these genes. We also obtained scores for the tools Nermal (biosemantics; literature mining) and FuncNet (which includes the literature mining tool iHop). Nermal turned out to have a good coverage of the proteome and for a large number of proteins Nermal was the only or one of the few tools providing a prediction. However, for other proteins FuncNet was more informative. For ranking purposes, we therefore included both the Nermal and the FuncNet scores.

Validation of the Ranking Approach

The ranking of all proteins based on FA-protein properties, resulted in a top 150 list (Table 3). The FA proteins score in general high, as can be expected since the scoring is based on their properties (Table 4). Furthermore, only 1673 unique associated gene names (including the FA proteins and proteins without a Nermal and/or FuncNet score) score 5 points or higher (Table 5) which is 7.5% of all unique associated gene names. The FANCF protein scored relatively low, compared to the other FA proteins. This could be attributed to the fact that in the automated scoring the mouse ortholog FANCF was missing, resulting in zero points for the human-mouse comparison feature. After manual correction of the percentage amino acid identity, FANCF ends up at the same level as FANCJ/BRIP1 and FANCD1/BRCA2 with 6.34 points. We hypothesized that in this particular ranking, a cut-off score ≥5 will select for FA like candidates (Table 4 and 5).
Table 3

Top 150 genes from the combined ranking.

PositionGene NameScorePositionGene NameScorePositionGene NameScore
1BRCA18.50051RAD51L36.461101IFIH16.303
2FANCG8.15652MAD1L16.452102XPA6.301
3FANCA8.13153BIN26.430103IRF36.294
4FANCC8.00554KIT6.428104CDKN1B6.293
5RPA17.86755SMARCAL16.426105ZNF2176.290
6BLM7.86656DBF46.417106CCNO6.290
7FANCD27.85457STAG36.416107PRDM26.284
8BARD17.73358PML6.408108RFC46.282
9RECQL57.72759BRIP16.405109SPO116.279
10XRCC37.69460NFE2L36.403110BCL36.275
11BCCIP7.69061CDKN1C6.398111NUP626.271
12FANCL7.63562PMS16.397112ITGB3BP6.270
13CHEK27.63163CDC25C6.389113TULP36.269
14FANCE7.61864CDKN1A6.384114ITGAE6.261
15NBN7.57865RAD516.377115PSMD96.260
16TP537.55466OGG16.376116E2F26.259
17RAD527.50867CCNA16.375117NAP1L26.259
18FANCB7.50068RAD51C6.372118MBD46.259
19MDC17.39269SUMO16.367119MLF16.259
20PMS27.35870TAF1B6.361120RAD54B6.257
21FANCM7.31171RTEL16.361121IFI356.257
22MUS817.29172MZF16.357122REV16.256
23ATRIP7.22373KNTC16.356123SRA16.254
24FANCI7.21474CDC76.354124ELP46.249
25BRF27.15275ZWINT6.353125ORC2L6.249
26IKBKE7.12976TP53BP16.351126CDC25B6.247
27DNA27.07477NCL6.349127MDM26.246
28PALB26.85478PNKP6.344128NDC806.243
29BUB16.80179MAP1S6.343129FOXN46.243
30BACH16.68980HMOX16.343130KIF116.242
31DCLRE1B6.65381BRCA26.341131TAF1A6.242
32DDX116.64882ERCC16.340132CASP86.240
33DDX126.64883SFRS16.338133ERCC56.240
34CCNE16.56884ATAD26.336134WDHD16.240
35RAD176.56585CHRNA46.335135NCAPD36.238
36NCOA36.55886CEP2506.330136RNASEL6.238
37RAD9A6.55087APEX26.329137NCOA46.238
38LIG16.54488LRPPRC6.327138HIF3A6.237
39ERCC66.53889CHFR6.327139RFX56.237
40RPA36.52690USP86.326140CCNF6.233
41GMNN6.50291RBBP86.325141KLF16.232
42BUB1B6.50092POLR2H6.325142TFDP36.232
43TTF26.49893RASSF76.324143CHEK16.231
44XRCC56.49294PPARGC1B6.322144DAPK36.228
45XRCC46.48895TRH6.319145NUP1536.228
46XRCC26.48696FOXM16.317146UIMC16.228
47NOP146.46997PRC16.313147SOD36.227
48MAPT6.46898NCAPH6.307148NEK36.226
49ZBTB326.46399SKAP16.307149FOXO46.224
50UBE2T6.463100TGFA6.305150UBASH3A6.224
Table 4

Scores for the sixteen known FA proteins.

Established FA proteinScore
FANCG8.16
FANCA8.13
FANCC8.00
FANCD27.85
FANCL7.64
FANCE7.62
FANCB7.50
FANCM7.31
FANCI7.21
FANCN/PALB26.85
XRCC26.49
FANCJ/BRIP16.41
FANCO/RAD51C6.37
FANCD1/BRCA26.34
FANCP/SLX45.01
FANCF4.34*

Manual inspection showed that the FANCF ortholog was not present in EnSEMBL (see Table 1), therefore FANCF should have scored 2 points higher.

Table 5

Distribution of scores in the ranked list.

Cut-off Score# Genes
≥3.0010610
≥4.007213
≥4.501749
≥5.001673
≥5.50919
≥6.00868
≥6.25123
≥6.5041
≥7.0027
Manual inspection showed that the FANCF ortholog was not present in EnSEMBL (see Table 1), therefore FANCF should have scored 2 points higher. Since only the first thirteen FA proteins were used for pipeline generation, we could also determine how the three newest members of the FA protein family, FANCO/RAD51C, FANCP/SLX4, and XRCC2 were performing (Table 4). The overall score for FANCO/RAD51C and XRCC2 turned out to be in the range of known FA proteins, while FANCP/SLX4 scored lower than known FA proteins. FANCP/SLX4 has a relatively high NLS score compared to the other FA proteins, even though we adjusted the NLS score for extremes. In addition, at the time of data retrieval no OMIM entry was present for SLX4. In the case of FA, there are strong candidates for FA genes uncovered by biochemical studies. These include the so-called FAAP proteins [30]–[33], which associate to the core complex, a nuclease FAN1 [34]–[37], and a deubiquitinating enzyme complex consisting of USP1 and UAF1 [38], [39]. These proteins, upon disruption, display the FA hallmarks including MMC sensitivity. Therefore, we were interested in how these proteins were ending up in our ranking (Table 6). Three of these, FAAP100, USP1, and FAAP24, would also have been suggested with our automated ranking scheme, with a respectively score of 6.15 (rank: 299), 5.44 (rank: 890), and 5.16 (rank: 1011). The protein UAF1 is a highly conserved in mouse (98% aa identity), and therefore had a score of 4.05 (no points for the conservation interval 40–85%). UAF1 functions as an activator of USP1 (by itself USP1 has almost no deubiquitinating activity), and the protein complex together functions as a deubiquitinating enzyme. Interestingly, it has been reported that UAF1 is an abundant protein in human cells, and that UAF1 may have additional functions [39], besides regulating the FA pathway. For the three other FAAPs (FAAP16∶4.05, FAAP20∶2.00, and FAAP10∶1.11) and FAN1 (4.53), manual correction of the orthology feature was required, as was the case FANCF. In addition, FAAP10 was not properly scored, due to the fact that the threshold for scoring of peptides was set at larger than 100 amino acids, and FAAP10 is 81 amino acids in length. Overall, the chosen settings leads to logical candidates in the top. However, awareness is important, since strong candidates may not show up by, for example, wrong mapping of orthologs.
Table 6

Scoring output for FA associated proteins.

Percentage identity (aa)
Associated proteinScoreHuman-MouseMouse-HumanNLS scorepILength* (aa)MIMInteractionGO nucleus
FAAP100/C17orf706.157361−0.474.897306113011
USP15.4488881.125.1378560347811
FAAP24/C19orf405.168179−0.229.702156108841−1
FAN1/MTMR154.5347652.307.3610171
FAAP16/MHF1/APITD14.05N/AN/A0.027.871646091301
UAF1/WDR484.059898−0.477.046776121671
FAAP20/C1orf862.003046−0.478.71283−1
FAAP10/MHF2/STRA131.11N/AN/A−0.475.69811

NLS and pI based on longest peptide.

The relatively large difference in percentage identity between human-mouse and mouse-human of FAN1/MTMR15 indicates a difference in sequence length. Indeed, upon manually checking the length for the human MTMR15 protein turned out to be 1017 aa (ENSP00000354497) and for the mouse ortholog 743 aa (ENSMUSP00000103138). When interrogating the FAN1 ortholog at NCBI HomoloGene, both proteins were of similar length and an identity score of 71% was predicted for human-mouse and mouse-human (Human: NP_055782.3, Mouse: NP_808561.2). The missing or wrong orthologs in EnsEMBL also contribute to the lower scoring of FAAP16 (human-mouse 78% amino acid identity; mouse-human 83% amino acid identity) and FAAP20 (human-mouse 53% amino acid identity; mouse-human 53% amino acid identity) and FAAP10 (human-mouse 64% amino acid identity; mouse-human 64% amino acid identity) when interrogating the orthologs at NCBI HomoloGene.

NLS and pI based on longest peptide. The relatively large difference in percentage identity between human-mouse and mouse-human of FAN1/MTMR15 indicates a difference in sequence length. Indeed, upon manually checking the length for the human MTMR15 protein turned out to be 1017 aa (ENSP00000354497) and for the mouse ortholog 743 aa (ENSMUSP00000103138). When interrogating the FAN1 ortholog at NCBI HomoloGene, both proteins were of similar length and an identity score of 71% was predicted for human-mouse and mouse-human (Human: NP_055782.3, Mouse: NP_808561.2). The missing or wrong orthologs in EnsEMBL also contribute to the lower scoring of FAAP16 (human-mouse 78% amino acid identity; mouse-human 83% amino acid identity) and FAAP20 (human-mouse 53% amino acid identity; mouse-human 53% amino acid identity) and FAAP10 (human-mouse 64% amino acid identity; mouse-human 64% amino acid identity) when interrogating the orthologs at NCBI HomoloGene. To further validate the method, we analyzed several proteins that are involved in DNA repair processes that the FA/BRCA pathway is coordinating, which include nucleolytic incision, translesion DNA synthesis (TLS), and homologous recombination [54] (Further see Table 7). Of the 26 analyzed proteins, 20 score above 5 points, of which 12 are also in the top 150: BRCA1, XRCC3, NBN/NBS1, RAD52, MUS81, XRCC2, RAD51L3/RAD51D, RAD51, ERCC1, RBBP8/CtIP, RAD54B, and REV1 (Table 3 and 7). REV1, is involved in translesion DNA synthesis and scores higher (6.26) than REV3 (4.22) and REV7 (3.14) that together form a complex called Pol ζ, mainly because the last two are highly conserved (more than 85%). REV1 functions as a scaffold protein to recruit and coordinate TLS polymerase, such as Pol ζ [55], [56]. Pol ζ has besides translesion DNA synthesis another essential role in cell proliferation [57]. The difference in score suggest that a high score (≥5) can distinguish between proteins that have a direct interaction with the FA/BRCA pathway (USP1 and REV1) and proteins that are coordinated via this link (UAF1 and Pol ζ).
Table 7

Overview proteins involved in processes coordinated by the FA/BRCA pathway.

ProteinScoreProcess*
BRCA18.50homologous recombination
XRCC37.69homologous recombination
NBN/NBS17.58homologous recombination
RAD527.51homologous recombination
MUS817.29nucleolytic incision
XRCC26.49homologous recombination
RAD51L3/RAD51D6.46homologous recombination
RAD516.38homologous recombination
ERCC16.34nucleolytic incision
RBBP8/CtIP6.33homologous recombination
RAD54B6.26homologous recombination
REV16.26translesion DNA synthesis
EME16.22nucleolytic incision
EME26.06nucleolytic incision
GEN16.05nucleolytic incision
RAD51L1/RAD51B5.86homologous recombination
MRE11A5.57homologous recombination
DMC15.52homologous recombination
ERCC4/XPF5.32nucleolytic incision
RAD505.17homologous recombination
RAD54L4.75homologous recombination
REV3/REV3L4.22translesion DNA synthesis
GIYD24.00nucleolytic incision
SHFM13.76homologous recombination
REV7/MAD2L23.14translesion DNA synthesis
GIYD13.00nucleolytic incision

Information based on http://sciencepark.mdanderson.org/labs/wood/DNA_Repair_Genes.html and [54].

Information based on http://sciencepark.mdanderson.org/labs/wood/DNA_Repair_Genes.html and [54]. In addition, we investigated a prime candidate for a novel FA gene based on whole-genome next generation sequencing data. The particular gene, PRR12, harboured two possible pathogenic mutations, which followed proper segregation as expected for a recessive disorder (unpublished data). However, based on our ranking system, this gene turned out to be an unlikely candidate, having only 1 point. Further functional testing, confirmed that PRR12 did not display the hallmark FA features. Upon PRR12 disruption by siRNA, the cells were still resistant to MMC. Furthermore, downregulation of PRR12 did not result in a reduction of RAD51 focus formation (Figure 2; Material and Methods S1), which is characteristic for the cells of the patient in which the PRR12 variants were found (unpublished data). This confirmed that a low score in our ranking corresponded to a non-FA protein (in this case).
Figure 2

Validation of FA candidate PRR12.

MMC growth inhibition assays and RAD51 foci in HeLa cells after siRNA knockdown with specific siRNAs for BRCA2, FANCD2, and PRR12 or with negative control siRNAs. A) MMC growth inhibition assays after siRNA knockdown of BRCA2 and FANCD2 show sensitivity to MMC. siRNA knockdown of PRR12 does not result in MMC sensitivity. Data represent average values from one representative experiment performed in triplicate. B) Relative gene expression was calculated via the 2−ΔΔCT method, normalized against the non targeting oligo and TBP. The normalized expression (average of two different primer sets per gene) of the non targeting oligo was set at 100%, and knockdown efficiency for BRCA2, FANCD2, and PRR12 siRNA has been indicated. C) siRNA knockdown of BRCA2 results in diminished RAD51 foci, whereas siRNA knockdown of FANCD2 and PRR12 show RAD51 foci after knockdown. Green: αRAD51; Red: αTOPRO3.

Validation of FA candidate PRR12.

MMC growth inhibition assays and RAD51 foci in HeLa cells after siRNA knockdown with specific siRNAs for BRCA2, FANCD2, and PRR12 or with negative control siRNAs. A) MMC growth inhibition assays after siRNA knockdown of BRCA2 and FANCD2 show sensitivity to MMC. siRNA knockdown of PRR12 does not result in MMC sensitivity. Data represent average values from one representative experiment performed in triplicate. B) Relative gene expression was calculated via the 2−ΔΔCT method, normalized against the non targeting oligo and TBP. The normalized expression (average of two different primer sets per gene) of the non targeting oligo was set at 100%, and knockdown efficiency for BRCA2, FANCD2, and PRR12 siRNA has been indicated. C) siRNA knockdown of BRCA2 results in diminished RAD51 foci, whereas siRNA knockdown of FANCD2 and PRR12 show RAD51 foci after knockdown. Green: αRAD51; Red: αTOPRO3. Furthermore, we evaluated the performance of the ranking scheme for identification of proteins enriched for functional classifications relevant to FA. A clear enrichment was found when screening the top 150 of the list for GO annotations “response to DNA damage stimulus” (GO:0006974; observed: 71; expected: 5; P-value: 5.50E−64) and “DNA repair” (GO:0006281; observed: 61; expected: 4; P-value: 1.28E−60; Figure 3). To demonstrate the effect of our combined scoring using multiple criteria, we also compared our top 150 list (“Ranked”) to the top 150 lists of the literature-mining tool “Nermal” and the protein function prediction tool “FuncNet”. When only FuncNet was used, the number of genes with the GO annotation for “response to DNA damage stimulus” (observed: 53; expected: 5; P-value: 4.27E−42) and “DNA repair” (observed: 47; expected: 3; P-value: 1.54E−42) were clearly lower compared to our ranking. However, the top 150 of Nermal “response to DNA damage stimulus” (observed: 65; expected: 5; P-value: 7.10E−56) and “DNA repair” (observed: 62; expected: 3; P-value: 1.24E−62) results in similar number of genes for the “DNA repair” annotation (Ranked: 61 genes and Nermal: 62 genes). To study the difference between our ranking (including Nermal and FuncNet) and Nermal alone, we also analyzed the remaining genes in the top 150 that do not have the “DNA repair” annotation for functional categories (Table 8 and 9). We chose for the “DNA repair” term so that both lists are comparable in size (for Ranked: 150 genes –61 genes with GO term “DNA repair” and 89 genes that do not have the GO term “DNA repair” and for Nermal: 150 genes –62 genes with GO term “DNA repair” and 88 genes that do not have the GO term “DNA repair”). In the case of our approach, the remaining genes were significantly enriched for cell cycle-regulated genes (10 most significant categories; all cell cycle; Table 8). The emphasis on cell cycle parallels the important role for FA proteins in the cell cycle. From the top 10 GO enrichments obtained for Nermal, only 4 GO terms were cell-cycle related (Table 9). The relation between the different cell-cycle related proteins uncovered by our approach (including Nermal and FuncNet) or with Nermal alone is shown in Figure 4.
Figure 3

GO enrichment top 150 of Ranked, Nermal, and FuncNet.

Number of genes observed with the GO terms “response to DNA damage stimulus” (GO:0006974) and “DNA repair” (GO:0006281) in the top 150 of our combined ranking approach “Ranked”, the literature mining tool “Nermal”, and the protein function prediction tool “FuncNet”. Number of genes observed, number of genes expected (P-value) for GO term “response to DNA damage stimulus” (GO:0006974): Ranked 71, 5 (5.50E−64); Nermal 65, 5 (7.10E−56); FuncNet 53, 5 (4.27E−42). GO term “DNA repair” (GO:0006281): Ranked 61, 4 (1.28E−60); Nermal 62, 3 (1.24E−62); FuncNet 47, 3 (1.54E−42).

Table 8

Top 10 biological processes for the combined ranking.

# Genes
GO-TermGO-Term idP-valueObservedExpectedTotal
cell cycle processGO:00224021.24E−23385.33888
cell cycle phaseGO:00224034.00E−23354.41735
mitotic cell cycleGO:00002782.62E−22333.98663
cell cycleGO:00070492.33E−21407.041173
regulation of cell cycle arrestGO:00711568.52E−16181.34223
regulation of cell cycleGO:00517263.32E−15253.51585
cell cycle arrestGO:00070504.27E−15201.97329
regulation of cell cycle processGO:00105645.08E−15201.99332
negative regulation of cell cycleGO:00457866.90E−15212.31385
cell cycle checkpointGO:00000757.67E−15171.28214

Biological process enrichment for the 89 remaining genes of the ranked top 150 that do not have the GO annotation “DNA repair” (GO:0006281). The 89 genes were analysed for enrichment via Genomatix GeneRanker. # Genes Observed = the number of genes from the input set which have this annotation; # Genes Expected = the number of genes one would expect to have this annotation based on the input set; # Genes Total = the number of genes from the complete genome which have this annotation.

Table 9

Top 10 biological processes for Nermal.

# Genes
GO-TermGO-Term idP-valueObservedExpectedTotal
negative regulation of cellular processGO:00485231.10E−113812.182104
negative regulation of biological processGO:00485191.62E−103813.302298
cell cycleGO:00070492.66E−08246.791173
cell proliferationGO:00082834.81E−08247.001210
cell cycle processGO:00224021.10E−07205.14888
protein modification by small protein conjugation or removalGO:00706471.34E−07142.46425
regulation of cell proliferationGO:00421271.47E−07205.23904
regulation of cell cycleGO:00517261.96E−07163.39585
protein modification by small protein conjugationGO:00324462.20E−07132.17375
negative regulation of cell cycleGO:00457862.97E−07132.23385

Biological process enrichment for the 88 remaining genes of the Nermal top 150 that do not have the GO annotation “DNA repair” (GO:0006281). The 88 genes were analysed for enrichment via Genomatix GeneRanker. # Genes Observed = the number of genes from the input set which have this annotation; # Genes Expected = the number of genes one would expect to have this annotation based on the input set; # Genes Total = the number of genes from the complete genome which have this annotation.

Figure 4

Overview genes involved in “Cell cycle process”, Ranked vs Nermal.

Analysis of the overlap between our combined approach and Nermal for the GO biological process term “Cell cycle process” (GO:0022402). Top 150 of either our combined ranking or Nermal alone were analyzed for GO term “DNA repair” (GO:0006281) and these genes were discarded. The remaining lists (Ranking combination scheme: 89 genes and Nermal: 88 genes) were further compared. In total, 7 genes were found in common (BACH1, NFE2L3, DDX11, CHEK2, MAPT, BUB1B, UBASH3A). A combined list of the remaining genes (Ranking: 81 genes and Nermal: 82 genes; total 163 genes) was analyzed with the Genomatix Pathway System (GePS). The biological process term “Cell cycle process” was the most enriched (P-value: 4.83E−25). The relation between the different cell cycle proteins is depicted (red: candidates combined ranking scheme, blue: candidates Nermal).

GO enrichment top 150 of Ranked, Nermal, and FuncNet.

Number of genes observed with the GO terms “response to DNA damage stimulus” (GO:0006974) and “DNA repair” (GO:0006281) in the top 150 of our combined ranking approach “Ranked”, the literature mining tool “Nermal”, and the protein function prediction tool “FuncNet”. Number of genes observed, number of genes expected (P-value) for GO term “response to DNA damage stimulus” (GO:0006974): Ranked 71, 5 (5.50E−64); Nermal 65, 5 (7.10E−56); FuncNet 53, 5 (4.27E−42). GO term “DNA repair” (GO:0006281): Ranked 61, 4 (1.28E−60); Nermal 62, 3 (1.24E−62); FuncNet 47, 3 (1.54E−42).

Overview genes involved in “Cell cycle process”, Ranked vs Nermal.

Analysis of the overlap between our combined approach and Nermal for the GO biological process term “Cell cycle process” (GO:0022402). Top 150 of either our combined ranking or Nermal alone were analyzed for GO term “DNA repair” (GO:0006281) and these genes were discarded. The remaining lists (Ranking combination scheme: 89 genes and Nermal: 88 genes) were further compared. In total, 7 genes were found in common (BACH1, NFE2L3, DDX11, CHEK2, MAPT, BUB1B, UBASH3A). A combined list of the remaining genes (Ranking: 81 genes and Nermal: 82 genes; total 163 genes) was analyzed with the Genomatix Pathway System (GePS). The biological process term “Cell cycle process” was the most enriched (P-value: 4.83E−25). The relation between the different cell cycle proteins is depicted (red: candidates combined ranking scheme, blue: candidates Nermal). Biological process enrichment for the 89 remaining genes of the ranked top 150 that do not have the GO annotation “DNA repair” (GO:0006281). The 89 genes were analysed for enrichment via Genomatix GeneRanker. # Genes Observed = the number of genes from the input set which have this annotation; # Genes Expected = the number of genes one would expect to have this annotation based on the input set; # Genes Total = the number of genes from the complete genome which have this annotation. Biological process enrichment for the 88 remaining genes of the Nermal top 150 that do not have the GO annotation “DNA repair” (GO:0006281). The 88 genes were analysed for enrichment via Genomatix GeneRanker. # Genes Observed = the number of genes from the input set which have this annotation; # Genes Expected = the number of genes one would expect to have this annotation based on the input set; # Genes Total = the number of genes from the complete genome which have this annotation. Proteins that participate in the same pathway usually display similar expression. As mentioned above, FA genes are expressed in a variety of tissues, but not at very high levels (cf. GeneNote profiles). The expression of a subset of mRNAs for FA genes is downregulated upon serum withdrawal and, although less strongly, upon reaching confluence, as for example tested in the human T98G cell model [58]. Genes such as DNA2, BUB1, DCLRE1B, DDX11 and GMNN from the top 150 list are similarly regulated for these cell cycle features and may display an as yet not recognized interaction with the FA network. So far, only biallelic/recessive mutations in the genes of the upstream branch (FANC-A, -B, -C, -E, -F, -G, -L, and -M) cause a clinical phenotype. The downstream branch, harbouring FANCD1/BRCA2, FANCN/PALB2, and FANCJ/BRIP1, both biallelic and/or monoallelic mutations result in a disease phenotype, notably breast cancer predisposition [59]. The top candidate in our ranking BRCA1, is another breast cancer predisposition gene. Interestingly, recently biallelic deleterious BRCA1 mutations were discovered in a 28 year-old woman diagnosed with ovarian cancer, who was extremely sensitive to DNA interstrand cross-linking chemotherapy [60]. Haploinsufficiency defines the state of a given gene where a single copy is insufficient to maintain normal function, which is one of the major causes of dominant diseases. We used recent data from Huang et al. (2010 [61]) to estimate the haploinsufficiency probability p(HI) in our top 150 genes. A p(HI) of 1 indicates high probability of haploinsufficiency, while 0 indicates haplosufficiency. We could determine p(HI) values for 143 genes resulting in a mean probability of 0.45 which is significantly different from the mean of 0.29 for the whole human set for which p(HI) could be predicted (Figure 5). To determine how the p(HI) is distributed over the 143 genes in our top 150 we plotted these against each other (Figure 6) and both genes with low and high p(HI) were detected, as expected. When comparing the group of genes with both a high ranking score (>6.75), and with almost opposite p(HI) values (<0.2 versus >0.9), four FA genes ended up in the first group, while established breast cancer predisposition genes ended up in the latter group. However, PALB2 has a low p(HI) value (Table 10). Interestingly, the five genes with a ranked score above 6.75 and a p(HI) value above 0.9 (TP53, BRCA1, RPA1, BUB1, and CHEK2) have Medical Subject Heading (MeSH) terms for small cell carcinoma (C04.557.470.200.380) and glioblastoma (C04.557.580.625.600.380.080.335, C04.557.470.670.380.080.335, C04.557.465.625.600.380.080.335). These data suggest that by overlaying the p(HI) score the top 150 can be divided in two groups, one containing the upstream branch and related genes, and the other group with the downstream branch related genes.
Figure 5

Distribution of haploinsufficiency probabilities (p(HI)).

Distribution of haploinsufficiency probabilities (p(HI)) for the human genome (from Huang et al. [61]). The mean p(HI) values for all human genes and 143 genes of our top 150 set are given as respectively, light blue and orange circles on the x-axis. p(HI)  = 1 means highly haploinsufficient, p(HI)  = 0 haplosufficient.

Figure 6

Distribution of scores of the top 150 vs p(HI).

The scores of the top 150 of our ranked approach were plotted against the p(HI) values of Huang et al. [61]. Shown are 143 genes, since 7 genes were not available in Huang’s data set.

Table 10

High scoring genes versus low (<0.2) and high (>0.9) p(HI).

Score Ranking >6.75
p(HI) <0.2p(HI) >0.9
PALB2TP53
RECQL5BRCA1
FANCBRPA1
FANCCBUB1
FANCMCHEK2
FANCE

Distribution of haploinsufficiency probabilities (p(HI)).

Distribution of haploinsufficiency probabilities (p(HI)) for the human genome (from Huang et al. [61]). The mean p(HI) values for all human genes and 143 genes of our top 150 set are given as respectively, light blue and orange circles on the x-axis. p(HI)  = 1 means highly haploinsufficient, p(HI)  = 0 haplosufficient.

Distribution of scores of the top 150 vs p(HI).

The scores of the top 150 of our ranked approach were plotted against the p(HI) values of Huang et al. [61]. Shown are 143 genes, since 7 genes were not available in Huang’s data set.

Application of Prioritization Approach

Ranking tools can be valuable to sort/sift through candidates obtained through whole exome sequencing experiments. In principle, the identification of a causal gene in the case of a recessive disorder, such as Fanconi anemia, is straightforward; the causal gene should harbour two pathogenic mutations (1 mutation in both copies). In practice, the situation may be more cumbersome. Genes harbouring two possible pathogenic mutations may turn out to be not the cause of the disease (see also above), while genes for which only one mutation has been reported may in fact require further study due to the fact that mutations could be missed owing to imperfections in the sequencing procedure, such as lack of coverage or complex mutation types not detectable by the technique. Lists of genes harbouring only one mutation will be inevitably significantly longer than lists of genes harbouring two mutations. Sifting through these lists may be significantly aided by specially tailored ranking tools which should be combined with manual curation.

Conclusion

We show how we used publicly available bioinformatics tools and databases to generate ranked lists tailored for FA-like genes. While the tools by themselves can be discriminative, an integrative approach exploiting multiple intrinsic features of FA proteins combined with functional and text mining resources may result in lists that are highly enriched for proteins of the network of interest. This kind of prioritization can be useful for Next Generation Sequencing projects to prioritize possible disease genes from an extensive list of candidates. Furthermore, since some of the FA proteins have been identified as genes involved in breast cancer we believe that our prioritization strategy can also be applied in studies to screen for breast cancer predisposition genes. (DOC) Click here for additional data file.
  60 in total

1.  GeneNote: whole genome expression profiles in normal human tissues.

Authors:  Orit Shmueli; Shirley Horn-Saban; Vered Chalifa-Caspi; Michael Shmoish; Ron Ophir; Hila Benjamin-Rodrig; Marilyn Safran; Eytan Domany; Doron Lancet
Journal:  C R Biol       Date:  2003 Oct-Nov       Impact factor: 1.583

2.  Evidence for at least four Fanconi anaemia genes including FACC on chromosome 9.

Authors:  C A Strathdee; A M Duncan; M Buchwald
Journal:  Nat Genet       Date:  1992-06       Impact factor: 38.330

3.  Evolutionary clues to the molecular function of fanconi anemia genes.

Authors:  Eric Blom; Henri J van de Vrugt; Johan P de Winter; Fré Arwert; Hans Joenje
Journal:  Acta Haematol       Date:  2002       Impact factor: 2.195

4.  X-linked inheritance of Fanconi anemia complementation group B.

Authors:  Amom Ruhikanta Meetei; Marieke Levitus; Yutong Xue; Annette L Medhurst; Michel Zwaan; Chen Ling; Martin A Rooimans; Patrick Bier; Maureen Hoatlin; Gerard Pals; Johan P de Winter; Weidong Wang; Hans Joenje
Journal:  Nat Genet       Date:  2004-10-24       Impact factor: 38.330

5.  A novel ubiquitin ligase is deficient in Fanconi anemia.

Authors:  Amom Ruhikanta Meetei; Johan P de Winter; Annette L Medhurst; Michael Wallisch; Quinten Waisfisz; Henri J van de Vrugt; Anneke B Oostra; Zhijiang Yan; Chen Ling; Colin E Bishop; Maureen E Hoatlin; Hans Joenje; Weidong Wang
Journal:  Nat Genet       Date:  2003-09-14       Impact factor: 38.330

6.  A 20-year perspective on the International Fanconi Anemia Registry (IFAR).

Authors:  David I Kutler; Bhuvanesh Singh; Jaya Satagopan; Sat Dev Batish; Marianne Berwick; Philip F Giampietro; Helmut Hanenberg; Arleen D Auerbach
Journal:  Blood       Date:  2002-09-26       Impact factor: 22.113

7.  Cancer incidence in persons with Fanconi anemia.

Authors:  Philip S Rosenberg; Mark H Greene; Blanche P Alter
Journal:  Blood       Date:  2002-09-05       Impact factor: 22.113

8.  Susceptibility of Fanconi's anemia lymphoblasts to DNA-cross-linking and alkylating agents.

Authors:  R Ishida; M Buchwald
Journal:  Cancer Res       Date:  1982-10       Impact factor: 12.701

9.  Biallelic inactivation of BRCA2 in Fanconi anemia.

Authors:  Niall G Howlett; Toshiyasu Taniguchi; Susan Olson; Barbara Cox; Quinten Waisfisz; Christine De Die-Smulders; Nicole Persky; Markus Grompe; Hans Joenje; Gerard Pals; Hideyuki Ikeda; Edward A Fox; Alan D D'Andrea
Journal:  Science       Date:  2002-06-13       Impact factor: 47.728

10.  Localisation of the Fanconi anaemia complementation group A gene to chromosome 16q24.3.

Authors:  J C Pronk; R A Gibson; A Savoia; M Wijker; N V Morgan; S Melchionda; D Ford; S Temtamy; J J Ortega; S Jansen
Journal:  Nat Genet       Date:  1995-11       Impact factor: 38.330

View more
  6 in total

Review 1.  TNF-α signaling in Fanconi anemia.

Authors:  Wei Du; Ozlem Erden; Qishen Pang
Journal:  Blood Cells Mol Dis       Date:  2013-07-24       Impact factor: 3.039

2.  AluY-mediated germline deletion, duplication and somatic stem cell reversion in UBE2T defines a new subtype of Fanconi anemia.

Authors:  Elizabeth L Virts; Anna Jankowska; Craig Mackay; Marcel F Glaas; Constanze Wiek; Stephanie L Kelich; Nadine Lottmann; Felicia M Kennedy; Christophe Marchal; Erik Lehnert; Rüdiger E Scharf; Carlo Dufour; Marina Lanciotti; Piero Farruggia; Alessandra Santoro; Süreyya Savasan; Kathrin Scheckenbach; Jörg Schipper; Martin Wagenmann; Todd Lewis; Michael Leffak; Janice L Farlow; Tatiana M Foroud; Ellen Honisch; Dieter Niederacher; Sujata C Chakraborty; Gail H Vance; Dmitry Pruss; Kirsten M Timms; Jerry S Lanchbury; Arno F Alpi; Helmut Hanenberg
Journal:  Hum Mol Genet       Date:  2015-06-17       Impact factor: 6.150

3.  Forkhead transcription factor FoxF1 interacts with Fanconi anemia protein complexes to promote DNA damage response.

Authors:  Arun Pradhan; Vladimir Ustiyan; Yufang Zhang; Tanya V Kalin; Vladimir V Kalinichenko
Journal:  Oncotarget       Date:  2016-01-12

4.  A novel Fanconi anaemia subtype associated with a dominant-negative mutation in RAD51.

Authors:  Najim Ameziane; Patrick May; Anneke Haitjema; Henri J van de Vrugt; Sari E van Rossum-Fikkert; Dejan Ristic; Gareth J Williams; Jesper Balk; Davy Rockx; Hong Li; Martin A Rooimans; Anneke B Oostra; Eunike Velleuer; Ralf Dietrich; Onno B Bleijerveld; A F Maarten Altelaar; Hanne Meijers-Heijboer; Hans Joenje; Gustavo Glusman; Jared Roach; Leroy Hood; David Galas; Claire Wyman; Rudi Balling; Johan den Dunnen; Johan P de Winter; Roland Kanaar; Richard Gelinas; Josephine C Dorsman
Journal:  Nat Commun       Date:  2015-12-18       Impact factor: 14.919

5.  Coregulation of FANCA and BRCA1 in human cells.

Authors:  Anneke Haitjema; Berber M Mol; Irsan E Kooi; Maarten Pg Massink; Jens Al Jørgensen; Davy Ap Rockx; Martin A Rooimans; Johan P de Winter; Hanne Meijers-Heijboer; Hans Joenje; Josephine C Dorsman
Journal:  Springerplus       Date:  2014-07-28

6.  Estrogen receptor-α promoter methylation is a biomarker for outcome prediction of cisplatin resistance in triple-negative breast cancer.

Authors:  Junnan Xu; Tao Sun; Xiangyu Guo; Yan Wang; Mingxi Jing
Journal:  Oncol Lett       Date:  2017-12-19       Impact factor: 2.967

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.